Denali PUBLIC | NASDAQ:DNLI Focus on neurodegenerative diseases such as Parkinson’s and Alzheimer’s http://www.denalitherapeutics.com/ Press Releases Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic Apr 2, 2020 Denali Therapeutics Announces Pricing of Public Offering of Common Stock Jan 29, 2020 Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights Nov 6, 2019 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website Sep 4, 2019 Denali Therapeutics Announces that its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study Aug 5, 2019 Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs Jun 11, 2019 Denali Therapeutics Reports First Quarter 2019 Financial Results May 7, 2019 Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights Mar 12, 2019 Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease Feb 15, 2019 Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS Jan 8, 2019 « Older Entries Press Coverage Multiple Sclerosis News Today: Denali and Sanofi Partner to Develop Potential Treatments for MS, Other Neurological Disorders Nov 6, 2018 BioWorld: Sanofi taps Denali to help tackle neurodegenerative, inflammatory diseases in $1B-plus collaboration Nov 2, 2018 Forbes: Milestone Moment: A Parkinson’s Drug Moves Forward With Help From Michael J.Fox Oct 25, 2018 BioWorld: Startups deploying an expanded toolbox to tackle Alzheimer’s disease Oct 19, 2018 GenomeWeb: Centogene, Denali Therapeutics Partner to Recruit Parkinson’s Patients for Drug Program Oct 3, 2018 ALZFORUM: Let ’Er RIP: ALS/FTD Variant Plus Aging Unleash Deadly Kinase Aug 31, 2018
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic Apr 2, 2020
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website Sep 4, 2019
Denali Therapeutics Announces that its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study Aug 5, 2019
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs Jun 11, 2019
Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease Feb 15, 2019
Multiple Sclerosis News Today: Denali and Sanofi Partner to Develop Potential Treatments for MS, Other Neurological Disorders Nov 6, 2018
BioWorld: Sanofi taps Denali to help tackle neurodegenerative, inflammatory diseases in $1B-plus collaboration Nov 2, 2018
GenomeWeb: Centogene, Denali Therapeutics Partner to Recruit Parkinson’s Patients for Drug Program Oct 3, 2018
